Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies

Ryo Ishino, Yumi Kawase, MD, Toshio Kitawaki, MD PhD, Naoshi Sugimoto, MD PhD, Maki Oku, MD, Shumpei Uchida, MD, Osamu Imataki, MD PhD, Akihito Matsuoka, MD PhD, Teruhisa Taoka, MD PhD, Kimihiro Kawakami, MD PhD, Tomoki Todo, MD PhD, Akifumi Takaori-Kondo, MD PhD, Norimitsu Kadowaki, MD PhD

Blood (2019) 134 (Supplement_1): 3242.

https://doi.org/10.1182/blood-2019-127754

Published: 2019

Journal Articles

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

Chikashi Yoshida, MD PhD, Noriyoshi Iriyama, MDPhD, Yuho Najima, Shin Fujisawa, MD PhD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD, PhD, Shinichiro Okamoto, MD PhD, Kimihiro Kawakami, MDPhD, Naoki Takezako, MD PhD, Takashi Kumagai, MD PhD, Kazuma Ohyashiki, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, MD PhD, Tadahiko Igarashi, MD, Yasuji Kouzai, MD PhD, Satoshi Morita, PhD Prof, Junichi Sakamoto, MD PhD, Hisashi Sakamaki, MD PhD, Koiti Inokuchi, MD PhD Prof

Blood (2016) 128 (22): 1916.

https://doi.org/10.1182/blood.V128.22.1916.1916

Published: 2016

Journal Articles

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Maki Hagihara, MDPhD, Noriyoshi Iriyama, MDPhD, Chikashi Yoshida, MD PhD, Shin Fujisawa, MD, Hisashi Wakita, MD PhD, Shigeru Chiba, MD PhD, Naoki Takezako, MD PhD, Kimihiro Kawakami, MD PhD, Shinichiro Okamoto, MD PhD, Koiti Inokuchi, MD PhD, Kazuma Ohyashiki, Takashi Kumagai, MD PhD, Jun Taguchi, MD PhD, Shingo Yano, Tadahiko Igarashi, MD PhD, Yasuji Kouzai, MD PhD, Junichi Sakamoto, MDPhD, Satoshi Morita, PhD, Hisashi Sakamaki, MDPhD

Blood (2014) 124 (21): 1795.

https://doi.org/10.1182/blood.V124.21.1795.1795

Published: 2014

Journal Articles

Chemotherapy for Acute Myeloid Leukemia Can Compensate Other Adverse Prognostic Factors in Elderly: A Retrospective Longitudinal Cohort Study in a Local Community, Japan

Osamu Imataki, MD, Hiroaki Ohnishi, MD, Yasunori Kawachi, M.D., Makoto Ide, M.D., Ph.D., Makiko Uemura, M.D., Kimihiro Kawakami, M.D., Ph.D., Akihito Matsuoka, M.D., Ph.D., Masato Waki, M.D., Ph.D., Hidetaka Takimoto, MD, Yasuo Hoshijima, M.D., Ph.D., Tetsuya Fukumoto, M.D., Ph.D., Kensuke Matsumoto, M.D., Ph.D., Fusako Waki, MD, Teruhisa Taoka, M.D., Ph.D., Takuya Matsunaga, MD, PhD

Blood (2012) 120 (21): 3582.

https://doi.org/10.1182/blood.V120.21.3582.3582

Published: 2012

Journal Articles

Physical Examination Can Predict the Risk of Infection in Patients with Febrile Neutropenia (FN)

Yotaro Tamai, Osamu Imataki, Kimihiro Kawakami, Terukazu Tanaka

Blood (2008) 112 (11): 4365.

https://doi.org/10.1182/blood.V112.11.4365.4365

Published: 2008

Journal Articles

The Utility of 18 F-FDG PET for Malignant Lymphoma; Single Cancer Center Survey.

Yotaro Tamai, Osamu Imataki, Kimihiro Kawakami, Terukazu Tanaka

Blood (2007) 110 (11): 4418.

https://doi.org/10.1182/blood.V110.11.4418.4418

Published: 2007

NARROW

Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Chemotherapy for Acute Myeloid Leukemia Can Compensate Other Adverse Prognostic Factors in Elderly: A Retrospective Longitudinal Cohort Study in a Local Community, Japan

Physical Examination Can Predict the Risk of Infection in Patients with Febrile Neutropenia (FN)

The Utility of 18 F-FDG PET for Malignant Lymphoma; Single Cancer Center Survey.

Email alerts

ASH Publications

American Society of Hematology

Oncolytic Virus Therapy with HSV-1 for Hematologic Malignancies

Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study

A Shorter Halving Time for BCR-ABL transcript Reduction Is a Novel Predictor of Molecular Response Achievement in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patients Treated with Dasatinib: Results of D-First Study

Chemotherapy for Acute Myeloid Leukemia Can Compensate Other Adverse Prognostic Factors in Elderly: A Retrospective Longitudinal Cohort Study in a Local Community, Japan

Physical Examination Can Predict the Risk of Infection in Patients with Febrile Neutropenia (FN)

The Utility of 18 F-FDG PET for Malignant Lymphoma; Single Cancer Center Survey.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only